P10636 |
TAU_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 |
TAU_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P10636 |
TAU_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 |
TAU_HUMAN |
Choreiform disorder [ICD-11: 8A01] |
P10636 |
TAU_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P10636 |
TAU_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 |
TAU_HUMAN |
Neurodegenerative disorder [ICD-11: 8A20-8A23] |
P11473 |
VDR_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
P11473 |
VDR_HUMAN |
Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 |
VDR_HUMAN |
Hyper-parathyroidism [ICD-11: 5A51] |
P11473 |
VDR_HUMAN |
Hypo-parathyroidism [ICD-11: 5A50] |
P11473 |
VDR_HUMAN |
Mineral deficiency [ICD-11: 5B5K] |
P11473 |
VDR_HUMAN |
Psoriasis [ICD-11: EA90] |
P11473 |
VDR_HUMAN |
Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 |
VDR_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P11473 |
VDR_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 |
VDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P11473 |
VDR_HUMAN |
Prostate disease [ICD-11: GA91] |
P11473 |
VDR_HUMAN |
Abnormal micturition [ICD-11: MF50] |
P11473 |
VDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 |
VDR_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 |
VDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
Q96KQ7 |
EHMT2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q96KQ7 |
EHMT2_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
Q96KQ7 |
EHMT2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P25779 |
CYSP_TRYCR |
Parasitic worm infestation [ICD-11: 1F90] |
P25779 |
CYSP_TRYCR |
Malaria [ICD-11: 1F40-1F45] |
Q03181 |
PPARD_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q03181 |
PPARD_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
Q03181 |
PPARD_HUMAN |
Autoimmune liver disease [ICD-11: DB96] |
Q03181 |
PPARD_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q03181 |
PPARD_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
Q03181 |
PPARD_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
Q03181 |
PPARD_HUMAN |
Dyslipidemia [ICD-11: 5C80-5C81] |
Q03181 |
PPARD_HUMAN |
Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q03181 |
PPARD_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
Q03181 |
PPARD_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P50579 |
MAP2_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
P50579 |
MAP2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P50579 |
MAP2_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P50579 |
MAP2_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |